CCM
ABUS icon

Cadence Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Cadence Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$159K Buy
+50,736
New +$154K 0.04% 275

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Cadence Capital Management's ABUS Position: Q3 2020 in Review

Cadence Capital Management opened a new position in Arbutus Biopharma (ABUS) in Q3 2020: 50,736 shares worth $159K. The stake represents 0.04% of the portfolio and ranks #275 among its holdings.

65 funds tracked by Wall St. Rank hold ABUS as of Q3 2020.

  • Cadence Capital Management held 50,736 shares of Arbutus Biopharma worth $159K as of Q3 2020.
  • Arbutus Biopharma was a new Cadence Capital Management position in Q3 2020.
  • Arbutus Biopharma made up 0.04% of Cadence Capital Management's portfolio in Q3 2020, its #275 holding.
  • 65 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.